Amgen (NASDAQ:AMGN) today announced new findings showing Repatha® (evolocumab) reduced the risk of d

Repatha is the First and Only PCSK9 Inhibitor Shown to Lower the Risk of Dying from All Causes, Incl

Amgen said Monday its cholesterol buster, Repatha, reduced the risk of death by 20% in a study of mo

Amgen is a diversified pharmaceutical giant with high net margins. It reported nearly $8.1 billion i

Blue Edge Capital LLC purchased a new stake in Amgen Inc. (NASDAQ: AMGN) during the second quarter,

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

AstraZeneca's Tezspire delivers positive CROSSING data in EoE, meeting all primary and secondary end

AstraZeneca & Amgen’s Tezspire achieves significant Phase 3 CROSSING trial results in eosinophil

Statistically significant and clinically meaningful disease and symptom improvements compared to pla

Arini Capital Management Ltd purchased a new stake in Amgen Inc. (NASDAQ: AMGN) during the second qu

Statistically Significant and Clinically Meaningful Disease and Symptom Improvements Compared to Pla

Statistically Significant and Clinically Meaningful Disease and Symptom Improvements Compared to Pla

Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 1.91% on an annualized bas

AMGN's strong growth drivers and promising pipeline support long-term growth, but patent losses, pri

On August 24, 2026, we conducted a discounted cash flow (DCF) analysis for Amgen Inc (AMGN), a compa

Allstate Corp reduced its holdings in shares of Amgen Inc. (NASDAQ: AMGN) by 6.7% during the undefin

Beutel Goodman and Co Ltd. lowered its holdings in shares of Amgen Inc. (NASDAQ: AMGN) by 19.8% in t

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investi

Bank of New York Mellon Corp decreased its position in Amgen Inc. (NASDAQ: AMGN) by 2.6% during the

VanEck's concentrated 25-stock biotech play offers higher volatility, while iShares' broader pharma

Piper Sandler analyst David Amsellem maintains Amgen (NASDAQ:AMGN) with a Overweight and raises t

Biotech ETFs are riding a powerful rally fueled by innovation, obesity drugs and M&A, with three fun

Aegis Wealth Management LLC acquired a new stake in Amgen Inc. (NASDAQ: AMGN) in the undefined quart

Alpine Woods Capital Investors LLC lifted its position in shares of Amgen Inc. (NASDAQ: AMGN) by 8.5

Among U.S. large-cap drugmakers, one name has clearly outrun the pack in 2026 so far.

Amgen (AMGN), the biotech heavyweight behind Repatha, Enbrel and MariTide, surged roughly 3.5% to $4

Argus Research analyst Jasper Hellweg maintains Amgen (NASDAQ:AMGN) with a Buy and raises the pri

BlackRock Inc. raised its position in Amgen Inc. (NASDAQ: AMGN) by 4.8% during the second quarter, a

On August 12, 2026, TScan Therapeutics, Inc. (the "Company") received notice from Amgen Inc.

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys

Mizuho analyst Salim Syed maintains Amgen (NASDAQ:AMGN) with a Neutral and raises the price targe

Cantor Fitzgerald analyst Carter Gould maintains Amgen (NASDAQ:AMGN) with a Neutral and raises th

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Barclays analyst Emily Field maintains Amgen (NASDAQ:AMGN) with a Equal-Weight and raises the pri

China’s science surge is reshaping global drug development as Washington moves to counter Beijing’s

The center will join Amgen's global Research and Development network, which consists of seven re

Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 1.65% on an annualized bas

Guggenheim analyst Vamil Divan maintains Amgen (NASDAQ:AMGN) with a Neutral and raises the price

Citigroup analyst Geoff Meacham maintains Amgen (NASDAQ:AMGN) with a Neutral and raises the price

Bill Baruch chose Amgen Inc. as his final trade, citing its strong Q2 results and raised guidance. M

Bernstein analyst Courtney Breen maintains Amgen (NASDAQ:AMGN) with a Market Perform and raises t

TD Cowen analyst Yaron Werber maintains Amgen (NASDAQ:AMGN) with a Buy and raises the price targe

Gold posts its biggest one-day gain since February and the Dow sets a record as Iran deal hopes cool

Truist Securities analyst Gregory Renza maintains Amgen (NASDAQ:AMGN) with a Hold and raises the

Oppenheimer analyst Jay Olson maintains Amgen (NASDAQ:AMGN) with a Outperform and raises the pric

Scotiabank analyst Louise Chen maintains Amgen (NASDAQ:AMGN) with a Sector Outperform and raises

RBC Capital analyst Luca Issi maintains Amgen (NASDAQ:AMGN) with a Outperform and raises the pric

Wells Fargo analyst Mohit Bansal maintains Amgen (NASDAQ:AMGN) with a Equal-Weight and raises the

BMO Capital analyst Evan David Seigerman maintains Amgen (NASDAQ:AMGN) with a Outperform and rais